| Predictive factors of response to treatment in patients with metastatic renal ... - UroToday |
|
|
UroToday Renal cell carcinoma represents approximately 3% of adult malignancies and 90-95% of neoplasms arising from the kidney. Many agents that target angiogenesis (eg, sunitinib, sorafenib, bevacizumab and pazopanib) and mTOR-targeted therapy (eg, |